The Lancet Neurology (neurology), The Lancet Oncology (oncology), and The Lancet Infectious Diseases (infectious diseases), all of which publish original research and reviews. These three ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with ...

More than two-thirds of stroke survivors have upper extremity paresis (ie, motor impairment affecting the arms and hands),1 and this impairment is typically treated with some amount of rehabilitation ...

The first evidence that removing amyloid plaques may delay Alzheimer’s symptoms has now been published. In The Lancet Neurology on March 19, scientists led by Randall Bateman at Washington University ...

An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

For individuals with dominantly inherited Alzheimer disease, long-term treatment with gantenerumab may delay clinical decline ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

One of the hallmarks of Alzheimer’s disease is when the protein amyloid sticks together and forms plaques in the brain.

An experimental drug reduced the risk of developing symptoms of Alzheimer's disease by half in people with a rare genetic ...